Delaware
|
|
94-3295878
|
(State
or other jurisdiction of
|
|
(I.R.S.
Employer
|
incorporation
or organization)
|
|
Identification
Number)
|
Title
of Each Class:
1
|
|
1
Name
of Each Exchange on Which Registered:
1
|
||||
Common
Stock, par value $0.0001 per share
|
|
The
NASDAQ Stock Market, LLC
|
Large
accelerated filer
o
|
|
Accelerated
filer
x
|
|
Non-accelerated
filer
o
|
Name
of Beneficial Owner
|
Shares
Owned
(1)
|
Shares Issuable
Pursuant
to
Options and
Warrants
Exercisable
Within
60 days of
February
9, 2007
|
Total
of
Shares
Beneficially
Owned
|
Percent
|
|||||||||
Named
Executive Officers:
|
|||||||||||||
Daniel
N. Swisher, Jr.
|
32,325
|
359,067
|
391,392
|
1.3
|
%
|
||||||||
Eric
H. Bjerkholt
|
2,567
|
122,720
|
125,287
|
*
|
|||||||||
Daniel
C. Adelman, M.D.
|
2,658
|
123,897
|
126,555
|
*
|
|||||||||
Daryl
B. Winter, Ph.D.(2)
|
73,185
|
87,278
|
160,463
|
*
|
|||||||||
James
W. Young, Ph.D.(3)
|
248,631
|
140,367
|
388,998
|
1.3
|
|||||||||
Directors,
not including CEO and Executive Chairman:
|
|||||||||||||
Anthony
B. Evnin, Ph.D.(4)
|
1,141,744
|
7,500
|
1,149,244
|
3.9
|
|||||||||
Stephen
P.A. Fodor, Ph.D.
|
_
|
41,030
|
41,030
|
*
|
|||||||||
Matthew
K. Fust
|
_
|
33,088
|
33,088
|
*
|
|||||||||
Steven
D. Goldby
|
_
|
41,030
|
41,030
|
*
|
|||||||||
Jonathan
S. Leff
|
3,626,879(5
|
)
|
249,046(6
|
)
|
3,875,925
|
13.0
|
|||||||
Homer
L. Pearce, Ph.D.
|
_
|
_
|
_
|
*
|
|||||||||
David
C. Stump, M.D.
|
_
|
_
|
_
|
*
|
|||||||||
James
A. Wells, Ph.D.(7)
|
320,882
|
153,383
|
474,265
|
1.6
|
|||||||||
All
directors and executive officers as a group
(13
persons)
|
5,448,871
|
1,358,406
|
6,807,277
|
22.1
|
%
|
||||||||
5%
Stockholders
|
|||||||||||||
Entities
affiliated with Alta Partners
|
1,932,464(8
|
)
|
579,739(9
|
)
|
2,512,203
|
8.4
|
%
|
||||||
Biogen
Idec(10)
|
2,912,022
|
_
|
2,912,022
|
9.9
|
|||||||||
Entities
affiliated with Credit Suisse First Boston(11)
|
3,406,490
|
_
|
3,406,490
|
11.6
|
|||||||||
Entities
affiliated with Deerfield
|
1,744,006(12
|
)
|
483,092(13
|
)
|
2,227,098
|
7.4
|
|||||||
Entities
affiliated with Warburg Pincus
|
3,626,875(5
|
)
|
241,546(6
|
)
|
3,868,421
|
13.0
|
|||||||
FMR
Corporation (Fidelity Management & Research
Corp.)
|
1,790,000
|
_
|
1,790,000
|
6.1
|
%
|
* |
Represents
beneficial ownership of less than one percent (1%) of the outstanding
shares of our common stock.
|
(1) |
This
table is based upon information provided to us by our executive officers
and directors and upon information about principal stockholders known
to
us based on Schedules 13G and 13D filed with the SEC. Unless otherwise
indicated in the relevant footnote to this table and subject to community
property laws where applicable, we believe that each of the stockholders
named in the table has sole voting and investment power with respect
to
the shares indicated as beneficially owned. Applicable percentages
of
beneficial ownerships are based on 29,453,510 shares of our common
stock
outstanding as of February 9, 2007, adjusted as required by SEC’s rules.
Includes shares of common stock subject to a right of repurchase
within
60 days of February 9, 2007 in the event the holder ceases to
provide services to us.
|
(2) |
On
April 17, 2007, Dr. Winter tendered his resignation, effective
as of May 17, 2007, as Senior Vice President of Intellectual Property
of our company.
|
(3) |
Includes
11,765 shares held by family members. Dr. Young disclaims beneficial
ownership of such shares, except to the extent of his pecuniary interest
therein.
|
(4) |
Includes
(i) 467,380 shares held by Venrock Associates, (ii) 649,955
shares held by Venrock Associates II, L.P., and (iii) 24,409 shares
held by Venrock Entrepreneur’s Fund, L.P. Anthony B. Evnin,
Michael C. Brooks, Eric S. Copeland, Bryan E. Roberts,
Ray A. Rothrock, Michael F. Tyrrell and Anthony Sun are the
general partners of Venrock Associates and Venrock Associates II,
L.P. These individuals may be deemed to share dispositive and voting
power
over the shares which are, or may be, deemed to be beneficially owned
by
Venrock Associates and Venrock Associates II, L.P. Each of these
individuals disclaims beneficial ownership of these shares, except
to the
extent of his or her pecuniary interest therein. The general partner
of
Venrock Entrepreneurs Fund, L.P. is Venrock Management LLC. Anthony
B.
Evnin, Michael C. Brooks, Eric S. Copeland, Bryan E.
Roberts, Ray A. Rothrock, Michael F. Tyrrell and Anthony Sun are
the members of Venrock Management LLC. These individuals may be deemed
to
share dispositive and voting power over the shares which are, or
may be,
deemed to be beneficially owned by Venrock Entrepreneurs Fund, L.P.
Each
of these individuals disclaims beneficial ownership of these shares,
except to the extent of his or her pecuniary interest therein. The
address
of Venrock Associates and its affiliates is 30 Rockefeller Plaza,
Room 5508, New York, New
York 10112.
|
(5) |
Includes
(i) 3,506,739 shares held by Warburg, Pincus Equity Partners, L.P.,
(ii) 109,214 shares held by Warburg, Pincus Netherlands Equity
Partners I, C.V., (iii) 10,922 shares held by Warburg, Pincus
Netherlands Equity Partners III, C.V., and (iv) for Mr. Leff
only, 4 shares held by his family members. Warburg Pincus Partners,
LLC, a subsidiary of Warburg Pincus & Co., is the sole general
partner of WPEP, WP Netherlands I and WP Netherlands III. Warburg
Pincus LLC manages WPEP, WP Netherlands I and WP Netherlands III.
Mr. Leff, one of our directors, is a Partner of Warburg,
Pincus & Co. and a Managing Director and Member of Warburg
Pincus LLC. Charles R. Kaye and Joseph P. Landy are Managing General
Partners of Warburg Pincus & Co. and Managing Members and
Co-Presidents of Warburg Pincus LLC. Messrs. Kay, Landy and Leff may
be deemed to have an indirect pecuniary interest in an indeterminate
portion of the shares held by the Warburg Pincus entities. Each of
these
individuals disclaims beneficial ownership of such shares, except
to the
extent of his pecuniary interest therein. The address of Warburg
Pincus
and its affiliates is 466 Lexington Avenue, New York, New York
10017.
|
(6) |
Includes
(i) 228,261 shares issuable upon exercise of warrants held by
Warburg, Pincus Equity Partners, L.P., (ii) 12,077 shares issuable
upon exercise of warrants held by Warburg, Pincus Netherlands Equity
Partners I, C.V., (iii) 1,208 shares issuable upon exercise of
warrants held by Warburg, Pincus Netherlands Equity Partners III,
C.V.,
and (iv) for Mr. Leff only, an option to purchase 7,500 shares
of our common stock. All such warrants are immediately
exercisable. Warburg Pincus Partners, LLC, a subsidiary of Warburg
Pincus & Co., is the sole general partner of WPEP, WP Netherlands
I and WP Netherlands III. Warburg Pincus LLC manages WPEP, WP
Netherlands I and WP Netherlands III. Mr. Leff, one of our directors,
is a Partner of Warburg, Pincus & Co. and a Managing Director and
Member of Warburg Pincus LLC. Charles R. Kaye and Joseph P. Landy are
Managing General Partners of Warburg Pincus & Co. and Managing
Members and Co-Presidents of Warburg Pincus LLC. Messrs. Kay, Landy
and Leff may be deemed to have an indirect pecuniary interest in
an
indeterminate portion of the shares held by the Warburg Pincus entities.
Each of these individuals disclaims beneficial ownership of such
shares,
except to the extent of his pecuniary interest therein. The address
of
Warburg Pincus and its affiliates is 466 Lexington Avenue, New York,
New York 10017.
|
(7) |
Includes
2,352 shares held by a family
member.
|
(8) |
Includes
(i) 118,870 shares held by Alta BioPharma Partners III
GmbH & Co. Beteiligungs KG, (ii) 1,769,975 shares held by
Alta BioPharma Partners III, L.P., and (iii) 43,619 shares held by
Alta Embarcadero BioPharma Partners III, LLC. Alta Partners
III, Inc. provides investment advisory services to Alta BioPharma
Partners III GmbH & Co. Beteiligungs KG, Alta BioPharma Partners
III, L.P. and Alta Embarcadero BioPharma Partners III, LLC, which
we refer
to collectively as the Alta Funds. The managing directors of Alta
BioPharma Management III, LLC, which is a general partner of Alta
BioPharma Partners III, L.P. and the managing limited partner of
Alta
BioPharma Partners III GmbH & Co. Beteiligungs KG, and the
managers of Alta Embarcadero BioPharma Partners III, LLC exercise
sole
dispositive and voting power over the shares owned by the Alta Funds.
Certain principals of Alta Partners III, Inc., Jean Deleage, Alix
Marduel, Farah Campsi, Edward Penhoet and Ed Hurwitz, are managing
directors of Alta BioPharma Management III, LLC and managers of Alta
Embarcadero BioPharma Partners III, LLC. These individuals may be
deemed
to share dispositive and voting power over the shares held by the
Alta
Funds. Each of these individuals disclaims beneficial ownership of
such
shares, except to the extent of his or her pecuniary interest therein.
The
address of Alta Partners III, Inc. and its affiliates is One
Embarcadero Center, 37th Floor, San Francisco, California
94111.
|
(9) |
Includes
(i) 35,661 shares issuable upon exercise of warrants held by Alta
BioPharma Partners III GmbH & Co. Beteiligungs KG, (ii)
530,992 shares issuable upon exercise of warrants held by Alta BioPharma
Partners III, L.P., and (iii) 13,086 shares issuable upon exercise of
warrants held by Alta Embarcadero BioPharma Partners III, LLC. All
such warrants are immediately exercisable. Alta Partners
III, Inc. provides investment advisory services to Alta BioPharma
Partners III GmbH & Co. Beteiligungs KG, Alta BioPharma Partners
III, L.P. and Alta Embarcadero BioPharma Partners III, LLC, which
we refer
to collectively as the Alta Funds. The managing directors of Alta
BioPharma Management III, LLC, which is a general partner of Alta
BioPharma Partners III, L.P. and the managing limited partner of
Alta
BioPharma Partners III GmbH & Co. Beteiligungs KG, and the
managers of Alta Embarcadero BioPharma Partners III, LLC exercise
sole
dispositive and voting power over the shares owned by the Alta Funds.
Certain principals of Alta Partners III, Inc., Jean Deleage, Alix
Marduel, Farah Campsi, Edward Penhoet and Ed Hurwitz, are managing
directors of Alta BioPharma Management III, LLC and managers of Alta
Embarcadero BioPharma Partners III, LLC. These individuals may be
deemed
to share dispositive and voting power over the shares held by the
Alta
Funds. Each of these individuals disclaims beneficial ownership of
such
shares, except to the extent of his or her pecuniary interest therein.
The
address of Alta Partners III, Inc. and its affiliates is One
Embarcadero Center, 37th Floor, San Francisco, California
94111.
|
(10) |
Biogen
Idec MA, Inc., a Massachusetts corporation, is a wholly-owned
subsidiary of Biogen Idec Inc., a Delaware corporation that is publicly
traded on the Nasdaq National Market. James C. Mullen, Bruce R. Ross
and Peter N. Kellogg are the directors and executive officers of
Biogen Idec MA, Inc. These individuals may be deemed to share
dispositive and voting power over the shares which are, or may be,
deemed
to be beneficially owned by Biogen Idec MA, Inc. Each of these
individuals disclaims beneficial ownership of these shares, except
to the
extent of his pecuniary interest
therein.
|
(11) |
Includes
(i) 175,775 shares held by EMA Partners Fund 2000, L.P., or EMA
Partners, (ii) 233,004 shares held by EMA Private Equity Fund 2000,
L.P., or EMA Private, (iii) 654,387 shares held by Credit Suisse
First Boston Equity Partners (Bermuda), L.P., or CSFB Bermuda,
(iv) 2,341,061 shares held by Credit Suisse First Boston Equity
Partners, L.P., or CSFB-EP, and (v) 2,263 shares held by Credit
Suisse First Boston U.S. Executive Advisors, L.P., or CSFB U.S. Credit
Suisse First Boston Advisory Partners, LLC, or CSFB Advisory, manages
the
investments of CSFB-EP, CSFB Bermuda and CSFB U.S. EMA Partners and
EMA
Private each must invest in and dispose of its portfolio securities
simultaneously with CSFB-EP on a pro-rata basis. CFSB Advisory may
be
deemed to have dispositive and voting power over the shares held
by
CSFB-EP, CSFB Bermuda, CSFB U.S., EMA Partners and EMA Private. Credit
Suisse Group, through a wholly-owned subsidiary, is a parent of CSFB
Advisory, and may be deemed to have dispositive and voting power
over the
shares held by CSFB-EP, CSFB Bermuda, CSFB U.S., EMA Partners and
EMA
Private. Credit Suisse Group disclaims beneficial ownership of the
shares
owned by such investment partnerships. The address of Credit Suisse
First
Boston and its affiliates is Eleven Madison Avenue, New York, New
York 10010.
|
(12) |
Includes
(i) 435,000 shares held by Deerfield International Limited,
(ii) 323,306 shares held by Deerfield Partners, L.P.,
(iii) 642,385 shares held by Deerfield Special Situations Fund
International, Ltd.,
and
(iv) 343,315 shares held by Deerfield Special Situations Fund, L.P.
James Flynn, investment manager of each of Deerfield International
Limited, Deerfield Partners, L.P., Deerfield Special Situations Fund
International, Ltd. and Deerfield Special Situations Fund, L.P. has
dispositive and voting power over the shares owned by these funds.
The
address of Deerfield and its affiliates is 780 Third Avenue, 37th
Floor, New York, New York 10017.
|
(13) |
Includes
(i) 127,000 shares issuable upon exercise of warrants held by
Deerfield International Limited, (ii) 99,092 shares issuable upon
exercise of warrants held by Deerfield Partners, L.P., (iii) 167,000
shares issuable upon exercise of warrants held by Deerfield Special
Situations Fund International, Ltd.,
and
(iv) 90,000 shares issuable upon exercise of warrants held by
Deerfield Special Situations Fund, L.P. All such warrants are immediately
exercisable. James Flynn, investment manager of each of Deerfield
International Limited, Deerfield Partners, L.P., Deerfield Special
Situations Fund International, Ltd. and Deerfield Special Situations
Fund,
L.P. has dispositive and voting power over the shares owned by these
funds. The address of Deerfield and its affiliates is 780
Third Avenue, 37th Floor, New York, New York
10017.
|
|
(A)
|
(B)
|
(C)
|
|||||||
Plan Category
|
Number of Securities
to be Issued
upon Exercise of
Outstanding Options
and Rights
|
Weighted Average
Exercise Price of
Outstanding Options
and Rights
|
Number of Securities
Remaining Available for
Future Issuance Under
Equity Compensation Plans
(Excluding Securities
Reflected in Column A)
|
|||||||
Equity
Compensation Plans Approved by Stockholders(1)
|
3,822,435(2
|
)
|
$
|
4.26
|
561,581(3
|
)
|
||||
Equity
Compensation Plans Not Approved by Stockholders(4)
|
120,000
|
$
|
5.71
|
80,000
|
||||||
Total
|
3,942,435
|
$
|
4.30
|
641,581
|
(1) |
Includes
our 1998 Stock Plan, or 1998 Plan, 2001 Stock Plan, or 2001 Plan,
2005
Equity Incentive Award Plan, or 2005 Plan, and Employee Stock
Purchase
Plan, or ESPP.
|
(2) |
Includes
(i) 1,310,370 shares of common stock issuable upon the exercise of
options granted under our 1998 Plan, all of which were exercisable
as of
December 31, 2006, (ii) 229,969 shares of common stock issuable
upon the exercise of options granted under our 2001 Plan, all of
which
were exercisable as of December 31, 2006, and (iii) 2,282,096
shares of common stock issuable upon the exercise of options granted
under
our 2005 Plan, 403,282 of which were exercisable as of December 31,
2006. Excludes purchase rights currently accruing under the ESPP.
Offering
periods under the ESPP are 12-month periods, which are comprised
of two
six-month purchase periods. Eligible employees may purchase shares
of
common stock at a price equal to 85% of the lower of the fair market
value
of the common stock at the beginning of each offering period or the
end of
each semi-annual purchase period. Participation is limited to 20%
of an
employee’s eligible compensation, subject to limitations under the
Code.
|
(3) |
Includes
(i) 396,716 shares of common stock available for issuance under our
2005 Plan and (ii) 164,865 shares of common stock available for
issuance under our ESPP. 202,941 shares of our common stock were
initially
reserved for issuance under our ESPP. The number of shares of common
stock
reserved under our ESPP will automatically increase on the first
trading
day each year, beginning in 2006, by an amount equal to the least
of: (i) 0.5% of our outstanding shares of common stock
outstanding on such date, (ii) 135,294 shares or (iii) a lesser
amount determined by our Board of Directors. The maximum aggregate
number
of shares which may be issued over the term of the ESPP is 1,352,941
shares.
|
(4) |
Our
2006 Employment Commencement Incentive Plan, or 2006 Plan, became
effective on January 1, 2006. Effective January 1, 2007, our
Board of Directors increased the 2006 Plan by an additional 200,000
shares
such that the aggregate number of shares of our common stock reserved
for
issuance under our 2006 Plan, which did not require stockholder approval
pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), is 400,000
shares.
|
|
SUNESIS
PHARMACEUTICALS, INC.
|
|||
|
|
By:
|
|
/s/ ERIC
H. BJERKHOLT
|
|
|
|
|
Eric
H. Bjerkholt
|
|
|
|
|
Senior
Vice President, Corporate Development
|
|
|
|
|
and
Finance, Chief Financial
Officer
|
Signature
|
|
|
|
Title
|
|
|
|
Date
|
|
|
/s/ JAMES
W. YOUNG, PH.D.
|
|
Executive
Chairman of the Board
|
|
May
23, 2007
|
||||||
James
W. Young, Ph.D.
|
|
|
|
|
||||||
/s/ DANIEL
N. SWISHER, JR.
|
|
President,
Chief Executive Officer and
|
|
May
23, 2007
|
||||||
Daniel
N. Swisher, Jr.
|
|
Director
(Principal
Executive Officer)
|
|
|
||||||
/s/ ERIC
H. BJERKHOLT
|
|
Senior
Vice President, Corporate Development
|
|
May
23, 2007
|
||||||
Eric
H. Bjerkholt
|
|
and
Finance, Chief Financial Officer
|
|
|
||||||
|
|
(Principal
Financial Officer
|
|
|
||||||
|
|
and
Principal Accounting Officer)
|
|
|
||||||
/s/ ANTHONY
B. EVNIN, PH.D.
|
|
Director
|
|
May
23, 2007
|
||||||
Anthony
B. Evnin, Ph.D.
|
|
|
|
|
||||||
/s/ STEPHEN
P.A. FODOR, PH.D.
|
|
Director
|
|
May
23, 2007
|
||||||
Stephen
P.A. Fodor, Ph.D.
|
|
|
|
|
||||||
/s/ MATTHEW
K. FUST
|
|
Director
|
|
May
23, 2007
|
||||||
Matthew
K. Fust
|
|
|
|
|
||||||
/s/ STEVEN
D. GOLDBY
|
|
Director
|
|
May
23, 2007
|
||||||
Steven
D. Goldby
|
|
|
|
|
||||||
/s/
JONATHAN S. LEFF
|
|
Director
|
|
May 23,
2007
|
||||||
Jonathan
S. Leff
|
|
|
|
|
||||||
/s/ HOMER
L. PEARCE, PH.D.
|
|
Director
|
|
May
23, 2007
|
||||||
Homer
L. Pearce
|
|
|
|
|
||||||
/s/ DAVID
C. STUMP, M.D.
|
|
Director
|
|
May
23, 2007
|
||||||
David
C. Stump, M.D.
|
|
|
|
|
||||||
/s/
JAMES A. WELLS, PH.D.
|
|
Director
|
|
May
23, 2007
|
||||||
James
A. Wells, Ph.D.
|
|
|
Exhibit
Number
|
|
Description
|
3.1**
|
|
Amended
and Restated Certificate of Incorporation of the
Registrant.
|
3.2**
|
Amended
and Restated Bylaws of the Registrant.
|
|
10.48*
|
S
|
Summary
of Non-Employee Director Compensation.
|
10.49*
|
Named
Executive Officer Compensation and Bonus Program.
|
|
31.1
|
|
Certification
of Chief Executive Officer as required by Rule 13a-14(a) of the
Securities Exchange Act of 1934, as amended.
|
31.2
|
|
Certification
of Chief Financial Officer as required by Rule 13a-14(a) of the
Securities Exchange Act of 1934, as
amended.
|
*
|
This
exhibit is a management contract or compensatory plan or arrangement
required to be filed as an exhibit pursuant to Item 15(b) of
Form 10-K.
|
** |
Exhibits
3.1 and 3.2 hereto update Exhibits 3.1 and 3.2 of the Company’s Form S-3
(Registration Statement No. 333-138736) and are incorporated by reference
therein.
|
Page
|
||
ARTICLE
I - CORPORATE OFFICES
|
1
|
|
1.1
|
REGISTERED
OFFICE
|
1
|
1.2
|
OTHER
OFFICES
|
1
|
ARTICLE
II - MEETINGS OF STOCKHOLDERS
|
1
|
|
2.1
|
PLACE
OF MEETINGS
|
1
|
2.2
|
ANNUAL
MEETING
|
1
|
2.3
|
SPECIAL
MEETING
|
1
|
2.4
|
ADVANCE
NOTICE PROCEDURES; NOTICE OF STOCKHOLDERS’ MEETINGS
|
2
|
2.5
|
MANNER
OF GIVING NOTICE; AFFIDAVIT OF NOTICE
|
3
|
2.6
|
QUORUM
|
3
|
2.7
|
ADJOURNED
MEETING; NOTICE
|
4
|
2.8
|
CONDUCT
OF BUSINESS
|
4
|
2.9
|
VOTING
|
4
|
2.10
|
STOCKHOLDER
ACTION BY WRITTEN CONSENT WITHOUT A
MEETING
|
4
|
2.11
|
RECORD
DATE FOR STOCKHOLDER NOTICE; VOTING; GIVING
CONSENTS
|
4
|
2.12
|
PROXIES
|
5
|
2.13
|
LIST
OF STOCKHOLDERS ENTITLED TO VOTE
|
5
|
2.14
|
INSPECTORS
OF ELECTION
|
5
|
ARTICLE
III - DIRECTORS
|
6
|
|
3.1
|
POWERS
|
6
|
3.2
|
NUMBER
OF DIRECTORS
|
6
|
3.3
|
ELECTION,
QUALIFICATION AND TERM OF OFFICE OF
DIRECTORS
|
6
|
3.4
|
RESIGNATION
AND VACANCIES
|
7
|
3.5
|
PLACE
OF MEETINGS; MEETINGS BY TELEPHONE
|
7
|
3.6
|
REGULAR
MEETINGS
|
8
|
3.7
|
SPECIAL
MEETINGS; NOTICE
|
8
|
3.8
|
QUORUM
|
8
|
3.9
|
BOARD
ACTION BY WRITTEN CONSENT WITHOUT A MEETING
|
8
|
3.10
|
FEES
AND COMPENSATION OF DIRECTORS
|
9
|
3.11
|
REMOVAL
OF DIRECTORS
|
9
|
ARTICLE
IV - COMMITTEES
|
9
|
|
4.1
|
COMMITTEES
OF DIRECTORS
|
9
|
4.2
|
COMMITTEE
MINUTES
|
9
|
4.3
|
MEETINGS
AND ACTION OF COMMITTEES
|
9
|
ARTICLE
V - OFFICERS
|
10
|
|
5.1
|
OFFICERS
|
10
|
5.2
|
APPOINTMENT
OF OFFICERS
|
10
|
Page
|
||
5.3
|
SUBORDINATE
OFFICERS
|
10
|
5.4
|
REMOVAL
AND RESIGNATION OF OFFICERS
|
11
|
5.5
|
VACANCIES
IN OFFICES
|
11
|
5.6
|
REPRESENTATION
OF SHARES OF OTHER CORPORATIONS
|
11
|
5.7
|
AUTHORITY
AND DUTIES OF OFFICERS
|
11
|
ARTICLE
VI - RECORDS AND REPORTS
|
11
|
|
6.1
|
MAINTENANCE
AND INSPECTION OF RECORDS
|
11
|
6.2
|
INSPECTION
BY DIRECTORS
|
12
|
ARTICLE
VII - GENERAL MATTERS
|
12
|
|
7.1
|
EXECUTION
OF CORPORATE CONTRACTS AND INSTRUMENTS
|
12
|
7.2
|
STOCK
CERTIFICATES; PARTLY PAID SHARES
|
12
|
7.3
|
SPECIAL
DESIGNATION ON CERTIFICATES
|
13
|
7.4
|
LOST
CERTIFICATES
|
13
|
7.5
|
CONSTRUCTION;
DEFINITIONS
|
13
|
7.6
|
DIVIDENDS
|
13
|
7.7
|
FISCAL
YEAR
|
13
|
7.8
|
SEAL
|
14
|
7.9
|
TRANSFER
OF STOCK
|
14
|
7.10
|
STOCK
TRANSFER AGREEMENTS
|
14
|
7.11
|
REGISTERED
STOCKHOLDERS
|
14
|
7.12
|
WAIVER
OF NOTICE
|
14
|
ARTICLE
VIII - NOTICE BY ELECTRONIC TRANSMISSION
|
15
|
|
8.1
|
NOTICE
BY ELECTRONIC TRANSMISSION
|
15
|
8.2
|
DEFINITION
OF ELECTRONIC TRANSMISSION
|
15
|
8.3
|
INAPPLICABILITY
|
16
|
ARTICLE
IX - INDEMNIFICATION
|
16
|
|
9.1
|
INDEMNIFICATION
OF DIRECTORS AND OFFICERS
|
16
|
9.2
|
INDEMNIFICATION
OF OTHERS
|
16
|
9.3
|
PREPAYMENT
OF EXPENSES
|
16
|
9.4
|
DETERMINATION;
CLAIM
|
16
|
9.5
|
NON-EXCLUSIVITY
OF RIGHTS
|
17
|
9.6
|
INSURANCE
|
17
|
9.7
|
OTHER
INDEMNIFICATION
|
17
|
9.8
|
AMENDMENT
OR REPEAL
|
17
|
ARTICLE
X - AMENDMENTS
|
17
|
(i) |
if
by facsimile telecommunication, when directed to a number at which
the
stockholder has consented to receive
notice;
|
(ii) |
if
by electronic mail, when directed to an electronic mail address at
which
the stockholder has consented to receive
notice;
|
(iii) |
if
by a posting on an electronic network together with separate notice
to the
stockholder of such specific posting, upon the later of (A) such
posting and (B) the giving of such separate notice; and
|
(iv) |
if
by any other form of electronic transmission, when directed to the
stockholder.
|
Annual Cash Retainer: | $ | 20,000 | ||
Annual Committee Fee: | $ | 3,000 | ||
Annual Committee Chair Fee: | $ | 5,000 |
Name
and Position
|
2007
Base Salary($)
|
|||
Daniel
N. Swisher, Jr
Chief
Executive Officer and President
|
390,000
|
|||
Eric
H. Bjerkholt
Senior
Vice President, Corporate Development and Finance,
Chief
Financial Officer
|
285,000
|
|||
Daniel
C. Adelman, M.D.
Senior
Vice President of Drug Discovery
|
300,000
|
|||
James
W. Young, Ph.D.
Executive
Chairman
|
200,000
|
1.
|
I
have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A
of
Sunesis Pharmaceuticals, Inc.
|
2.
|
Based
on my knowledge, this report does not contain any untrue statement
of a
material fact or omit to state a material fact necessary to make
the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this
report.
|
Date:
May 23, 2007
|
|
|
|
/s/
Daniel N. Swisher, Jr.
|
|
|
Daniel
N. Swisher, Jr.
|
|
|
Chief Executive Officer and President
|
|
1.
|
I
have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A
of
Sunesis Pharmaceuticals, Inc.
|
2.
|
Based
on my knowledge, this report does not contain any untrue statement
of a
material fact or omit to state a material fact necessary to make
the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this
report.
|
Date:
May 23, 2007
|
|
|
|
/s/
Eric H. Bjerkholt
|
|
|
Eric
H. Bjerkholt
|
|
|
Senior
Vice President, Corporate Development and
|
|
Finance,
Chief Financial Officer
|